Published in

Taylor and Francis Group, OncoImmunology, 9(7), p. e1468953

DOI: 10.1080/2162402x.2018.1468953

Links

Tools

Export citation

Search in Google Scholar

Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma

Journal article published in 2018 by Fabio Morandi ORCID, Loredana Amoroso ORCID, Alessandra Dondero ORCID, Roberta Castriconi ORCID, Stefano Parodi ORCID, Roberto Luksch ORCID, Fiorina Casale ORCID, Aurora Castellano, Alberto Garaventa ORCID, Alessandro Moretta, Cristina Bottino ORCID, Mirco Ponzoni ORCID, Maria Valeria Corrias ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO